Optimizing bevacizumab dosing in glioblastoma: less is more
- 30 June 2017
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 135 (1) , 99-105
Abstract
Compared to traditional chemotherapies, where dose limiting toxicities represent the maximum possible dose, monoclonal antibody therapies are used at doses well below maximum tolerated dose. However, there has been little effort to ascertain whether there is a submaximal dose at which the efficacy/complication ratio is maximized. Thus, despite the general practice of using Bevacizumab (BEV) at dosages of 10 mg/kg every other week for glioma patients, there has not been much prior work examining whether the relatively high complication rates reported with this agent can be decreased by lowering the dose without impairing efficacy. We assessed charts from 80 patients who received BEV for glioblastoma to survey the incidence of complications relative to BEV dose. All patients were treated with standard upfront chemoradiation. The toxicity was graded based on the NCI CTCAE, version 4.03. The rate of BEV serious related adverse events was 12.5% (n = 10/80). There were no serious adverse events (≥grade 3) when the administered dose was (<3 mg/kg/week), compared to a 21% incidence in those who received higher doses (≥3 mg/kg/week) (P < 0.01). Importantly, the three patient deaths attributable to BEV administration occurred in patients receiving higher doses. Patients who received lower doses also had a better survival rate, although this did not reach statistical significance [median OS 39 for low dose group vs. 17.3 for high dose group (P = 0.07)]. Lower rates of serious BEV related toxicities are noted when lower dosages are used without diminishing positive clinical impact. Further work aimed at optimizing BEV dosage is justified.Keywords
This publication has 30 references indexed in Scilit:
- Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohortsJournal of Neuro-Oncology, 2011
- Reversible modulations of neuronal plasticity by VEGFProceedings of the National Academy of Sciences, 2011
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences, 2011
- A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomasCancer, 2010
- Novel Designs and End Points for Phase II Clinical TrialsClinical Cancer Research, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 casesJournal of Neurosurgery, 2008
- Dose Selection in Phase I Studies: Why We Should Always Go for the TopJournal of Clinical Oncology, 2008
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416Clinical Cancer Research, 2005